Published in J Exp Clin Cancer Res on August 02, 2014
Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma | NCT01239368
Collection of Tissue Samples for Study of Multidrug Resistance | NCT00880503
Endocannabinoid system as a regulator of tumor cell malignancy - biological pathways and clinical significance. Onco Targets Ther (2016) 1.14
DDR2 facilitates hepatocellular carcinoma invasion and metastasis via activating ERK signaling and stabilizing SNAIL1. J Exp Clin Cancer Res (2015) 0.99
Blockade of CXCL12/CXCR4 signaling inhibits intrahepatic cholangiocarcinoma progression and metastasis via inactivation of canonical Wnt pathway. J Exp Clin Cancer Res (2014) 0.91
MiR-133a suppresses the migration and invasion of esophageal cancer cells by targeting the EMT regulator SOX4. Am J Transl Res (2015) 0.91
P-Cadherin Linking Breast Cancer Stem Cells and Invasion: A Promising Marker to Identify an "Intermediate/Metastable" EMT State. Front Oncol (2015) 0.91
Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells. Oncogene (2016) 0.84
SULF2 overexpression positively regulates tumorigenicity of human prostate cancer cells. J Exp Clin Cancer Res (2015) 0.84
Characterization of genome-wide TFCP2 targets in hepatocellular carcinoma: implication of targets FN1 and TJP1 in metastasis. J Exp Clin Cancer Res (2015) 0.83
Clinical significance of pancreatic circulating tumor cells using combined negative enrichment and immunostaining-fluorescence in situ hybridization. J Exp Clin Cancer Res (2016) 0.83
MiR-137 and miR-34a directly target Snail and inhibit EMT, invasion and sphere-forming ability of ovarian cancer cells. J Exp Clin Cancer Res (2016) 0.82
Methylation status of insulin-like growth factor-binding protein 7 concurs with the malignance of oral tongue cancer. J Exp Clin Cancer Res (2015) 0.82
CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis. PLoS One (2016) 0.82
MicroRNA-338-3p suppresses metastasis of lung cancer cells by targeting the EMT regulator Sox4. Am J Cancer Res (2016) 0.82
Short hairpin RNA- mediated gene knockdown of FOXM1 inhibits the proliferation and metastasis of human colon cancer cells through reversal of epithelial-to-mesenchymal transformation. J Exp Clin Cancer Res (2015) 0.81
DAL-1 attenuates epithelial-to mesenchymal transition in lung cancer. J Exp Clin Cancer Res (2015) 0.81
Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines. J Exp Clin Cancer Res (2015) 0.80
Store-operated Ca(2+) entry regulates glioma cell migration and invasion via modulation of Pyk2 phosphorylation. J Exp Clin Cancer Res (2014) 0.80
Inhibition of SALL4 reduces tumorigenicity involving epithelial-mesenchymal transition via Wnt/β-catenin pathway in esophageal squamous cell carcinoma. J Exp Clin Cancer Res (2016) 0.80
Mouse double minute 2 (MDM2) upregulates Snail expression and induces epithelial-to-mesenchymal transition in breast cancer cells in vitro and in vivo. Oncotarget (2016) 0.79
Cisplatin promotes mesenchymal-like characteristics in osteosarcoma through Snail. Oncol Lett (2016) 0.77
Overshoot during phenotypic switching of cancer cell populations. Sci Rep (2015) 0.77
Ionizing radiation promotes advanced malignant traits in nasopharyngeal carcinoma via activation of epithelial-mesenchymal transition and the cancer stem cell phenotype. Oncol Rep (2016) 0.77
Snail heterogeneity in clear cell renal cell carcinoma. BMC Cancer (2016) 0.77
The transcription factors Slug (SNAI2) and Snail (SNAI1) regulate phospholipase D (PLD) promoter in opposite ways towards cancer cell invasion. Mol Oncol (2015) 0.76
Associations of chemo- and radio-resistant phenotypes with the gap junction, adhesion and extracellular matrix in a three-dimensional culture model of soft sarcoma. J Exp Clin Cancer Res (2015) 0.76
Snail1 is required for the maintenance of the pancreatic acinar phenotype. Oncotarget (2016) 0.76
TET3 inhibits TGF-β1-induced epithelial-mesenchymal transition by demethylating miR-30d precursor gene in ovarian cancer cells. J Exp Clin Cancer Res (2016) 0.76
Interleukin-11 promotes epithelial-mesenchymal transition in anaplastic thyroid carcinoma cells through PI3K/Akt/GSK3β signaling pathway activation. Oncotarget (2016) 0.76
Induction of the mesenchymal to epithelial transition by demethylation-activated microRNA-125b is involved in the anti-migration/invasion effects of arsenic trioxide on human chondrosarcoma. J Exp Clin Cancer Res (2016) 0.76
KSHV-Mediated Regulation of Par3 and SNAIL Contributes to B-Cell Proliferation. PLoS Pathog (2016) 0.75
Role of RbBP5 and H3K4me3 in the vicinity of Snail transcription start site during epithelial-mesenchymal transition in prostate cancer cell. Oncotarget (2016) 0.75
Integrin and dystroglycan compensate each other to mediate laminin-dependent basement membrane assembly and epiblast polarization. Matrix Biol (2016) 0.75
Snail levels control the migration mechanism of mesenchymal tumor cells. Oncol Lett (2016) 0.75
PP2A inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin resistance in medulloblastoma cells. Oncotarget (2016) 0.75
Clinical significance of detecting circulating tumor cells in colorectal cancer using subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH). Oncotarget (2017) 0.75
Effects of irradiation on radioresistance, HOTAIR and epithelial-mesenchymal transition/cancer stem cell marker expression in esophageal squamous cell carcinoma. Oncol Lett (2017) 0.75
MiR-548c impairs migration and invasion of endometrial and ovarian cancer cells via downregulation of Twist. J Exp Clin Cancer Res (2016) 0.75
Rs2853677 modulates Snail1 binding to the TERT enhancer and affects lung adenocarcinoma susceptibility. Oncotarget (2016) 0.75
Platelet-derived growth factor-C promotes human melanoma aggressiveness through activation of neuropilin-1. Oncotarget (2017) 0.75
Epithelial-to-mesenchymal transition in FHC-silenced cells: the role of CXCR4/CXCL12 axis. J Exp Clin Cancer Res (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell (2006) 120.51
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 32.82
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology (1991) 30.87
The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol (2000) 21.15
The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell (1982) 19.91
Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol (1993) 10.65
The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol (2002) 10.59
Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol (2004) 9.80
Matrix metalloproteinases: a review. Crit Rev Oral Biol Med (1993) 9.03
Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science (1997) 8.99
The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development (2005) 8.42
Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer (2004) 8.06
Fibronectins: multifunctional modular glycoproteins. J Cell Biol (1982) 8.05
Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell (2010) 7.20
Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development (1993) 6.56
Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature (1980) 5.84
Fibronectin at a glance. J Cell Sci (2002) 5.51
Regulation of PTEN transcription by p53. Mol Cell (2001) 5.44
Snail blocks the cell cycle and confers resistance to cell death. Genes Dev (2004) 5.34
E-cadherin null mutant embryos fail to form a trophectoderm epithelium. Proc Natl Acad Sci U S A (1994) 5.31
Dynamic regulation of histone lysine methylation by demethylases. Mol Cell (2007) 5.14
Functional correlation between cell adhesive properties and some cell surface proteins. J Cell Biol (1977) 4.97
Links between signal transduction, transcription and adhesion in epithelial bud development. Nature (2003) 4.88
The mouse snail gene encodes a key regulator of the epithelial-mesenchymal transition. Mol Cell Biol (2001) 4.80
Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell (2009) 4.73
A structural scaffolding of intermediate filaments in health and disease. Science (1998) 4.70
MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell (2003) 4.52
Epithelial mucin genes. Annu Rev Physiol (1995) 4.29
Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene (2002) 4.20
Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol (2004) 4.15
Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature (1999) 3.99
Identification of a putative cell adhesion domain of uvomorulin. EMBO J (1985) 3.85
Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol (2002) 3.82
Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci (2011) 3.80
Regulation of tight junctions during the epithelium-mesenchyme transition: direct repression of the gene expression of claudins/occludin by Snail. J Cell Sci (2003) 3.79
The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci (2008) 3.77
Direct evidence for a role of beta-catenin/LEF-1 signaling pathway in induction of EMT. Cell Biol Int (2002) 3.40
Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer (2005) 3.26
Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells (2009) 3.25
Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell (2009) 3.22
Snail induction of epithelial to mesenchymal transition in tumor cells is accompanied by MUC1 repression and ZEB1 expression. J Biol Chem (2002) 3.18
Wnt-dependent regulation of the E-cadherin repressor snail. J Biol Chem (2005) 3.03
'Hard' and 'soft' principles defining the structure, function and regulation of keratin intermediate filaments. Curr Opin Cell Biol (2002) 3.00
Interspecies diversity of the occludin sequence: cDNA cloning of human, mouse, dog, and rat-kangaroo homologues. J Cell Biol (1996) 2.94
Epithelial to mesenchymal transition: expression of the regulators snail, slug, and twist in pancreatic cancer. Clin Cancer Res (2007) 2.92
The Drosophila developmental gene snail encodes a protein with nucleic acid binding fingers. Nature (1987) 2.89
Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene (2007) 2.87
Aberrant expression of the transcription factors snail and slug alters the response to genotoxic stress. Mol Cell Biol (2004) 2.80
A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression. EMBO J (2005) 2.71
Human 92- and 72-kilodalton type IV collagenases are elastases. J Biol Chem (1991) 2.71
Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J Cell Sci (2001) 2.68
Phosphorylation regulates the subcellular location and activity of the snail transcriptional repressor. Mol Cell Biol (2003) 2.46
Regulation of Snail transcription during epithelial to mesenchymal transition of tumor cells. Oncogene (2004) 2.44
Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail. EMBO J (2006) 2.38
Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol (2001) 2.36
ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1. Oncogene (2010) 2.25
HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition. J Biol Chem (2008) 2.22
Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res (2003) 2.20
A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J Cell Biol (2011) 2.19
Unraveling signalling cascades for the Snail family of transcription factors. Cell Signal (2005) 2.17
G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer. J Clin Invest (2012) 2.12
Reverse correlation of E-cadherin and snail expression in oral squamous cell carcinoma cells in vitro. Oral Oncol (2001) 2.12
Pak1 phosphorylation of snail, a master regulator of epithelial-to-mesenchyme transition, modulates snail's subcellular localization and functions. Cancer Res (2005) 2.09
IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res (2011) 2.08
Cooperation between snail and LEF-1 transcription factors is essential for TGF-beta1-induced epithelial-mesenchymal transition. Mol Biol Cell (2006) 2.06
The SNAG domain of Snail1 functions as a molecular hook for recruiting lysine-specific demethylase 1. EMBO J (2010) 2.04
The transcription factors Slug and Snail act as repressors of Claudin-1 expression in epithelial cells. Biochem J (2006) 2.03
The LIM protein AJUBA recruits protein arginine methyltransferase 5 to mediate SNAIL-dependent transcriptional repression. Mol Cell Biol (2008) 2.00
Loss of E-cadherin expression in melanoma cells involves up-regulation of the transcriptional repressor Snail. J Biol Chem (2001) 1.98
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget (2012) 1.96
Loss of tight junction barrier function and its role in cancer metastasis. Biochim Biophys Acta (2008) 1.95
The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-alpha. Mol Endocrinol (2007) 1.95
Induction of a beta-catenin-LEF-1 complex by wnt-1 and transforming mutants of beta-catenin. Oncogene (1997) 1.83
Role of Ras signaling in the induction of snail by transforming growth factor-beta. J Biol Chem (2008) 1.83
The EIIIA segment of fibronectin is a ligand for integrins alpha 9beta 1 and alpha 4beta 1 providing a novel mechanism for regulating cell adhesion by alternative splicing. J Biol Chem (2002) 1.81
Snail1 transcriptional repressor binds to its own promoter and controls its expression. Nucleic Acids Res (2006) 1.80
Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate (2006) 1.78
Cancer stem cells: are we missing the target? J Natl Cancer Inst (2004) 1.72
EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer (2012) 1.70
Repression of PTEN phosphatase by Snail1 transcriptional factor during gamma radiation-induced apoptosis. Mol Cell Biol (2008) 1.68
Cross-talk of WNT and FGF signaling pathways at GSK3beta to regulate beta-catenin and SNAIL signaling cascades. Cancer Biol Ther (2006) 1.68
Complete structure of the human gene for 92-kDa type IV collagenase. Divergent regulation of expression for the 92- and 72-kilodalton enzyme genes in HT-1080 cells. J Biol Chem (1991) 1.68
Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. J Clin Oncol (2006) 1.67
Inverse correlation between E-cadherin and Snail expression in hepatocellular carcinoma cell lines in vitro and in vivo. Br J Cancer (2002) 1.66
Oncogenic regulation and function of keratins 8 and 18. Cancer Metastasis Rev (1996) 1.61
RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem (2004) 1.61
Lymphoid enhancer factor/T cell factor expression in colorectal cancer. Cancer Metastasis Rev (2004) 1.53
Gli1 acts through Snail and E-cadherin to promote nuclear signaling by beta-catenin. Oncogene (2007) 1.53
Snail: More than EMT. Cell Adh Migr (2010) 1.53
Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int (2003) 1.52
MUC1: a multifunctional cell surface component of reproductive tissue epithelia. Reprod Biol Endocrinol (2004) 1.52
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature (2013) 1.52
Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate (2002) 1.52
Snail accelerates cancer invasion by upregulating MMP expression and is associated with poor prognosis of hepatocellular carcinoma. Br J Cancer (2005) 1.51
Snail is a repressor of RKIP transcription in metastatic prostate cancer cells. Oncogene (2007) 1.50
Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res (2003) 2.01
Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance. J Clin Oncol (2004) 1.73
The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo. Leuk Res (2010) 1.59
Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Res (2004) 1.46
The activated NF-kappaB-Snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs. Crit Rev Immunol (2009) 1.46
Expression of KLF4 is a predictive marker for survival in pediatric Burkitt lymphoma. Leuk Lymphoma (2014) 1.44
Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res (2007) 1.39
Expression of transcription factor Yin Yang 1 in prostate cancer. Int J Oncol (2005) 1.37
Chemokine monokine induced by IFN-gamma/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and effector cytokine production. J Immunol (2004) 1.35
Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene (2004) 1.30
NF-kappaB in the pathogenesis and treatment of multiple myeloma. Curr Opin Hematol (2008) 1.25
Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res (2004) 1.25
Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence. Clin Cancer Res (2007) 1.23
Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int J Oncol (2007) 1.21
Overexpression of VEGF and TGF-beta1 mRNA in Pap smears correlates with progression of cervical intraepithelial neoplasia to cancer: implication of YY1 in cervical tumorigenesis and HPV infection. Int J Oncol (2007) 1.15
Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF. J Surg Res (2007) 1.15
Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis. Int J Oncol (2003) 1.14
The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN Circuit. Genes Cancer (2010) 1.14
Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. J Immunol (2008) 1.13
Understanding tobacco smoke carcinogen NNK and lung tumorigenesis. Int J Oncol (2006) 1.13
Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther (2004) 1.12
Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation. J Immunol (2007) 1.12
Nitric oxide donors: novel cancer therapeutics (review). Int J Oncol (2008) 1.12
Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther (2003) 1.08
Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene (2005) 1.07
Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis. Clin Immunol (2006) 1.06
Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Oncogene (2004) 1.06
Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Prostate (2002) 1.06
Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol (2012) 1.06
Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor. Blood (2006) 1.05
Mechanisms of nitric oxide-mediated inhibition of EMT in cancer: inhibition of the metastasis-inducer Snail and induction of the metastasis-suppressor RKIP. Cell Cycle (2010) 1.04
Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization. Cancer Res (2009) 1.01
Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther (2007) 1.00
Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions. Clin Cancer Res (2009) 0.97
TRAF6 activation in multiple myeloma: a potential therapeutic target. Clin Lymphoma Myeloma Leuk (2012) 0.96
The NO TRAIL to YES TRAIL in cancer therapy (review). Int J Oncol (2007) 0.96
Retracted Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction. Cancer Res (2010) 0.95
Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade). J Immunol (2006) 0.95
Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kappaB inhibitor DHMEQ. Curr Pharm Des (2009) 0.94
Expression of phosphorylated raf kinase inhibitor protein (pRKIP) is a predictor of lung cancer survival. BMC Cancer (2011) 0.94
Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis. Cell Cycle (2011) 0.94
Reversal of tumor resistance to apoptotic stimuli by alteration of membrane fluidity: therapeutic implications. Adv Cancer Res (2007) 0.94
Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1. Nitric Oxide (2008) 0.94
Inhibition of the transcription factor Yin Yang 1 activity by S-nitrosation. Biochem Biophys Res Commun (2005) 0.92
Role of CD8+ lymphocytes in chronic rejection of transplanted hearts. J Thorac Cardiovasc Surg (2002) 0.90
The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-κB/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis. Int J Oncol (2011) 0.90
Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. Br J Haematol (2007) 0.89
Higher expression levels of 14-3-3sigma in ductal carcinoma in situ of the breast predict poorer outcome. Cancer Biomark (2009) 0.89
Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma. Cancer (2004) 0.88
Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes. Int J Oncol (2003) 0.87
Lethal iron deprivation induced by non-neutralizing antibodies targeting transferrin receptor 1 in malignant B cells. Leuk Lymphoma (2011) 0.86
The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan. Br J Haematol (2009) 0.86
A potential mechanism of rituximab-induced inhibition of tumor growth through its sensitization to tumor necrosis factor-related apoptosis-inducing ligand-expressing host cytotoxic cells. Leuk Lymphoma (2010) 0.86
The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs. Leuk Lymphoma (2008) 0.86
In vitro and in vivo sensitization of SW620 metastatic colon cancer cells to CDDP-induced apoptosis by the nitric oxide donor DETANONOate: Involvement of AIF. Nitric Oxide (2008) 0.86
Prognostic significance of second mitochondria-derived activator of caspase (Smac/DIABLO) expression in bladder cancer and target for therapy. Int J Oncol (2010) 0.86
Mechanism of norepinephrine-mediated inhibition of human NK cytotoxic functions: inhibition of cytokine secretion, target binding, and programming for cytotoxicity. Brain Behav Immun (2002) 0.86
An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies. J Immunother (2011) 0.86
BRAF and RKIP are significantly decreased in cutaneous squamous cell carcinoma. Cell Cycle (2009) 0.85
HIF-1 expression is associated with CCL2 chemokine expression in airway inflammatory cells: implications in allergic airway inflammation. Respir Res (2012) 0.85
Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent. Drug Resist Updat (2007) 0.84
A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance. Adv Cancer Res (2002) 0.84
Galiximab signals B-NHL cells and inhibits the activities of NF-κB-induced YY1- and snail-resistant factors: mechanism of sensitization to apoptosis by chemoimmunotherapeutic drugs. Mol Cancer Ther (2012) 0.84
Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine. Cancer Biother Radiopharm (2002) 0.83
LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma. Int J Oncol (2006) 0.83
Inhibition of NF-kappaB and Akt pathways by an antibody-avidin fusion protein sensitizes malignant B-cells to cisplatin-induced apoptosis. Int J Oncol (2010) 0.83
YY1 Over-expression in human brain gliomas and meningiomas correlates with TGF-beta1, IGF-1 and FGF-2 mRNA levels. Cancer Invest (2009) 0.82
Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth. Blood (2007) 0.82
Viral infection and cancer: the NF-kappaB/Snail/RKIP loop regulates target cell sensitivity to apoptosis by cytotoxic lymphocytes. Crit Rev Immunol (2010) 0.82
Potentiation of cytotoxicity by combination of imatinib and chlorimipramine in glioma. Int J Oncol (2008) 0.81
Nitric oxide-mediated activity in anti-cancer photodynamic therapy. Nitric Oxide (2013) 0.81
Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. Clin Cancer Res (2002) 0.81
Prognostic significance of a combination of thymidylate synthase and dihydropyrimidine dehydrogenase activities in grades 1 and 2 superficial bladder cancer. Oncol Rep (2002) 0.80
Contribution of either YY1 or BclXL-induced inhibition by the NO-donor DETANONOate in the reversal of drug resistance, both in vitro and in vivo. YY1 and BclXL are overexpressed in prostate cancer. Nitric Oxide (2012) 0.79
Combination treatment of malignant B cells using the anti-CD20 antibody rituximab and the anti-malarial artesunate. Int J Oncol (2009) 0.79
Low circulating serum levels of second mitochondria-derived activator of caspase (Smac/DIABLO) in patients with bladder cancer. Int J Oncol (2012) 0.78
Dysregulation of the cell survival/anti-apoptotic NF-kappaB pathway by the novel humanized BM-ca anti-CD20 mAb: implication in chemosensitization. Int J Oncol (2009) 0.77
Regulated interleukin-10 expression prevents chronic rejection of transplanted hearts. J Thorac Cardiovasc Surg (2003) 0.77
Mechanism of activation of human peripheral blood NK cells at the single cell level by Echinacea water soluble extracts: recruitment of lymphocyte-target conjugates and killer cells and activation of programming for lysis. Int Immunopharmacol (2003) 0.77
Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine. Int J Oncol (2013) 0.77
Unique Pattern of Overexpression of Raf-1 Kinase Inhibitory Protein in Its Inactivated Phosphorylated Form in Human Multiple Myeloma. For Immunopathol Dis Therap (2011) 0.77
Serum pleiotrophin levels are elevated in multiple myeloma patients and correlate with disease status. Br J Haematol (2006) 0.77
Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapy. Methods Mol Biol (2011) 0.77
A novel angiogenesis model for screening anti-angiogenic compounds: the chorioallantoic membrane/feather bud assay. Int J Oncol (2010) 0.76
Quantitative structure-activity relationships of phenolic compounds causing apoptosis. Bioorg Med Chem (2003) 0.76
Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer. Cancer Biother Radiopharm (2002) 0.75
Actinomycin D-mediated sensitization of AIDS-Kaposi's sarcoma cells to Fas-mediated apoptosis: involvement of the mitochondrion-dependent pathway. Int J Oncol (2002) 0.75
QSAR of apoptosis induction in various cancer cells. Bioorg Med Chem (2003) 0.75